LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

LLY

1,078.15

+1.06%↑

JNJ

230.66

-1.67%↓

ABBV

214.25

-0.87%↓

UNH

378.22

-2.56%↓

AZN

188.44

+0.64%↑

Начало・Списък с акции・Incyte Corp

Incyte Corp

Отворен

СекторЗдравеопазване

96.85 -0.19

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

96.01

Максимум

97.89

Ключови измерители
By Trading Economics
Приходи	4.1M 303M
Продажби	-234M 1.3B
P/E Средно за сектора	13.445 49.701
EPS	1.81
Марж на печалбата	23.834
Служители	2,844
EBITDA	-47M 367M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+11.46% upside

Дивиденти
By Dow Jones
Следващи печалби	28.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-31M 19B
Предишно отваряне	97.04
Предишно затваряне	96.85

Настроения в новините

By Acuity

43%

57%

131 / 345 Класиране в Healthcare

Incyte Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

25.05.2026 г., 08:24 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25.05.2026 г., 21:22 ч. UTC

Печалби

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Basic Materials Roundup: Market Talk

25.05.2026 г., 16:01 ч. UTC

Пазарно говорене

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25.05.2026 г., 14:43 ч. UTC

Пазарно говорене

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25.05.2026 г., 14:15 ч. UTC

Пазарно говорене

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25.05.2026 г., 13:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

25.05.2026 г., 12:58 ч. UTC

Пазарно говорене

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25.05.2026 г., 12:56 ч. UTC

Пазарно говорене

Печалби

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25.05.2026 г., 12:48 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

25.05.2026 г., 12:34 ч. UTC

Пазарно говорене

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25.05.2026 г., 12:10 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Delivery Hero's Assets Look Strategic -- Market Talk

25.05.2026 г., 11:00 ч. UTC

Пазарно говорене

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25.05.2026 г., 10:19 ч. UTC

Пазарно говорене

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25.05.2026 г., 10:05 ч. UTC

Печалби

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25.05.2026 г., 10:04 ч. UTC

Печалби

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25.05.2026 г., 10:03 ч. UTC

Печалби

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25.05.2026 г., 10:02 ч. UTC

Печалби

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25.05.2026 г., 10:01 ч. UTC

Печалби

Tenaga Nasional 1Q Net Up 3.7% on Year

25.05.2026 г., 10:00 ч. UTC

Печалби

Tenaga Nasional 1Q Rev Up 6.6% on Year

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q EPS MYR0.1883

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Rev MYR17.1B

25.05.2026 г., 09:56 ч. UTC

Печалби

Tenaga Nasional 1Q Net MYR1.1B

25.05.2026 г., 09:38 ч. UTC

Пазарно говорене

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

25.05.2026 г., 09:33 ч. UTC

Пазарно говорене

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25.05.2026 г., 08:55 ч. UTC

Пазарно говорене

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Incyte Corp Прогноза

Ценова цел

By TipRanks

11.46% нагоре

12-месечна прогноза

Среден 108.29 USD 11.46%

Висок 135 USD

Нисък 75 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Incyte Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

19 ratings

Купи

Задържане

Продай

Според 19 анализатори, дали борсови рейтинги на Incyte Corp през последните 3 месеца.

Настроение

By Acuity

131 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Incyte Corp

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation